Search

Your search keyword '"Buch M"' showing total 444 results

Search Constraints

Start Over You searched for: Author "Buch M" Remove constraint Author: "Buch M"
444 results on '"Buch M"'

Search Results

1. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis

2. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

3. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

4. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

5. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

6. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

7. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

10. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

11. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

12. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

13. Points à considérer de l’EULAR sur l’initiation ou la reprise d’un traitement ciblé chez un patient atteint de rhumatisme inflammatoire chronique ayant un antécédent de cancer

14. Long COVID research: an update from the PHOSP-COVID Scientific Summit

18. POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

20. POS0853 EFFICACY OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA): WEEK (W) 156 RESULTS FROM A LONG-TERM EXTENSION (LTE) STUDY

21. POS0627 BLOOD-BASED PROTEIN BIOMARKERS ARE ASSOCIATED WITH SUBCLINICAL CARDIOVASCULAR ABNORMALITIES AS DEFINED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING IN SYSTEMIC SCLEROSIS (SSc) PATIENTS

22. OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

24. POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT

27. OP0130 ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL

29. POS0308 LONG-TERM CLINICAL PROFILE OF FILGOTINIB (FIL) IN PATIENTS (PTS) WITH RHEUMATOID ARTHRITIS (RA) BY CARDIOVASCULAR (CV) RISK FACTORS: A POST HOC SUBGROUP ANALYSIS

30. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

31. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

32. Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry

33. POS0704 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY

34. POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY

35. POS0107 ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

36. POS0110 INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS STRATIFIED BY GEOGRAPHIC REGION AND BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

39. POS0512 ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING

40. POS0237 MAJOR ADVERSE CARDIOVASCULAR EVENTS, MALIGNANCIES AND VENOUS THROMBOEMBOLISM BY BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

41. OP0264 IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME

45. AB0394 CLINICAL OUTCOMES UP TO WEEK 48 OF ONGOING FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) LONG-TERM EXTENSION (LTE) TRIAL OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (bDMARD) INADEQUATE RESPONDERS (IR) INITIALLY ON FIL OR PLACEBO IN A PHASE 3 PARENT STUDY (PS)

47. POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

48. OP0190 COMPREHENSIVE GENETIC AND FUNCTIONAL ANALYSES OF Fc GAMMA RECEPTORS EXPLAIN RESPONSE TO RITUXIMAB THERAPY FOR AUTOIMMUNE RHEUMATIC DISEASES

49. POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

Catalog

Books, media, physical & digital resources